Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a licensing agreement with the University of Alabama at Birmingham (UAB) to support research in B cell development.
Agreement Details
Under the agreement, Dr. James Kobie of UAB will receive a non-exclusive license to develop fully human antibodies using Nona’s H2L2 Harbour Mice platform. The collaboration aims to address fundamental issues in human B cell receptor libraries and develop monoclonal antibodies with therapeutic and diagnostic potential for infectious diseases and tumors.-Fineline Info & Tech
Leave a Reply